Dissecting the Anatomy of Corruption that Took Over the Federal Health Agencies and Our Economy
Story at a Glance
Large randomized controlled trials cost tens of millions of dollars, which turns drug approval into a pay-to-play process only industry can afford and creates enormous pressure to manipulate the results (a playbook I detailed last month).
The agencies meant to catch this are financially and professionally captured: industry user fees now fund roughly half the FDA’s budget, nearly every recent FDA commissioner has left for a pharmaceutical company, and scientists who push back are marginalized, surveilled, or driven out.
At the NIH, compliance is enforced through control of research grants (which Fauci was notorious for weaponizing) and through massive royalties from partnerships with the pharmaceutical industry.
Because the agencies cannot legally take corporate money directly, industry routes it through nominally independent “foundations” that act as legal bribery channels, shielded from FOIA and staffed by future pharmaceutical executives.
Leaked NIH emails show Bill Gates used this foundation structure to effectively merge his private foundation with the NIH (much like he did with the WHO), buying influence over the federal research agenda while profiting from the vaccine investments that agenda favored.
NIH emails (and earlier work) also show the captured apparatus was used to build much of the COVID response years in advance, around a plan centered entirely on vaccines, with no place for the cheap effective treatments that would have undercut it.
Last month, I highlighted the unfortunate state of medical research where “science” that supports corporate interests is held to much lower standards than science which opposes those interests, thereby ensuring “the science” becomes what benefits industry rather than the American people. The central vehicles for this are large randomized controlled trials, something which in theory seems like an excellent idea as they can eliminate unwanted bias and lead us to the truth. Unfortunately, large RCTs suffer from four major issues:
